Latest Regulatory News

Lachlan Star Limited reports promising maiden drilling results at its Killaloe Gold Project in Western Australia and initiates copper-gold drilling at North Cobar, NSW, while securing permits for further Basin Creek exploration.

Astute Metals NL sharpens its focus on Nevada’s rich mineral landscape, unveiling fresh high-grade gold targets at Needles and reaffirming lithium potential at Red Mountain amid leadership changes.

Amplia Therapeutics has launched a $27.5 million capital raising to advance its lead drug Narmafotinib, a promising FAK inhibitor showing superior efficacy in pancreatic cancer trials. The funds will support ongoing and new clinical studies, positioning the company for pivotal regulatory milestones.

Amplia Therapeutics has successfully raised A$25 million through an institutional placement and launched a A$2.5 million Share Purchase Plan to fund pivotal clinical trials of its lead drug narmafotinib. The capital injection positions the company to advance key pancreatic and ovarian cancer studies into 2027.

Bowen Coking Coal’s initial attempt to defer state royalty payments has been declined by the Queensland Revenue Office, prompting plans for a revised proposal amid ongoing debt restructuring efforts.

Latrobe Magnesium Limited has addressed ASX concerns over recent share price and volume spikes, attributing the market activity to recognition of its asset value and the imminent start of its demonstration plant.

Emmerson Resources’ latest Scoping Study confirms the White Devil Gold Project as a Major Mine, projecting robust financial returns and a seven-year mine life. With feasibility studies underway and a strategic JV structure, the project is poised for development in the Northern Territory.

West Wits Mining has released an updated Definitive Feasibility Study for its Qala Shallows project, revealing significant financial improvements and increased ore reserves. The study highlights a stronger gold price environment and refined mine plans that reduce capital requirements and accelerate payback.

Macarthur Minerals has updated its rights issue prospectus, introducing a cap on the underwriter's shareholding and revising key offer terms. These changes aim to balance funding needs with shareholder control and regulatory compliance.

NeuroScientific Biopharmaceuticals has completed its acquisition of StemSmart technology, reporting promising clinical results in Crohn’s disease and GVHD, alongside a $3.5 million capital raise to fuel next-stage development.

Lithium Plus Minerals reports key regulatory and environmental milestones for its Lei Lithium Development Project, progressing towards a near-term direct shipped ore operation backed by a strategic partnership with Canmax Technologies.

Elsight Limited reports record-breaking revenue growth in Q2 and H1 2025, driven by major defence contracts and expanding market opportunities, positioning the company for profitability later this year.